← back to search

Sabine Haufe

Heidelberg University · DE
Area of research
Endocrinology, Diabetes and Metabolism · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Thyroid Cancer Diagnosis and Treatment, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Treatment and Research, and Pediatric Urology and Nephrology Studies.
h-index
18
citations
3,078
works
48
NIH funding
primary concept
email

Recent publications

The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma
Radiotherapy and Oncology 2021cited by 29position: middledoi
Intraindividual Comparison of <sup>99m</sup>Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand <sup>99m</sup>Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer
Journal of Nuclear Medicine 2018cited by 44position: middledoi
BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer
Hormone and Metabolic Research 2018cited by 14position: middledoi
Warum braucht die Nephrologie heute noch die Nierenszintigraphie?
Der Nephrologe 2018cited by 0position: middledoi
Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
European Journal of Nuclear Medicine and Molecular Imaging 2017cited by 514position: middledoi
Erratum to: Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
European Journal of Nuclear Medicine and Molecular Imaging 2017cited by 8position: middledoi
[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty
Clinical Genitourinary Cancer 2017cited by 6position: middledoi
Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
European Journal of Nuclear Medicine and Molecular Imaging 2013cited by 18position: middledoi
Erratum to: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
European Journal of Nuclear Medicine and Molecular Imaging 2013cited by 17position: middledoi
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
European Journal of Nuclear Medicine and Molecular Imaging 2012cited by 922position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Uwe Haberkorn · Heidelberg University8 papers (2012–2021)Clemens Kratochwil · German Center for Lung Research7 papers (2012–2018)Frederik L. Giesel · Düsseldorf University Hospital7 papers (2012–2018)Tim Holland-Letz · Heidelberg University6 papers (2012–2018)Ali Afshar‐Oromieh · University Hospital of Bern6 papers (2012–2018)Matthias Eder · German Cancer Research Center5 papers (2012–2017)Hendrik Rathke · Kantonsspital Graubünden4 papers (2017–2021)Walter Mier · Heidelberg University3 papers (2017–2018)Klaus Kopka · Helmholtz-Zentrum Dresden-Rossendorf3 papers (2017–2017)Christian M. Zechmann · Heidelberg University3 papers (2012–2013)A. Malcher · Heidelberg University3 papers (2012–2013)Heinz Linhart · German Cancer Research Center3 papers (2012–2013)Boris Hadaschik · Deutsche Gesellschaft für Urologie3 papers (2012–2013)Michael Eisenhut · Luton and Dunstable University Hospital NHS Foundation Trust3 papers (2012–2017)Hans‐Ulrich Kauczor · German Cancer Research Center2 papers (2017–2017)Nils Debus · Heidelberg University2 papers (2017–2017)Markus Hohenfellner · Chirurgische Universitätsklinik Heidelberg2 papers (2017–2017)Michael Eisenhut · Luton and Dunstable University Hospital NHS Foundation Trust2 papers (2013–2017)Christophe Kremer · University Hospital Heidelberg2 papers (2017–2018)Jürgen Debus · NYU Langone Health2 papers (2017–2021)